Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 10, 2013, Pages 1152-1159

  Mimura, Shunya ^a   Ando, Takafumi ^a   Ishiguro, Kazuhiro ^a   Maeda, Osamu ^a   Watanabe, Osamu ^a   Ujihara, Masaki ^a   Hirayama, Yutaka ^a   Morise, Kazuhiro ^a   Maeda, Keiko ^a   Matsushita, Masanobu ^a   Funasaka, Kohei ^a   Nakamura, Masanao ^a   Miyahara, Ryoji ^a   Ozaki, Nobuaki ^a   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

Dipeptidyl peptidase 4; Glucagon like polypeptide 2; Inflammatory bowel disease

Indexed keywords

ANAGLIPTIN; DEXTRAN SULFATE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; KI 67 ANTIGEN; MESSENGER RNA; MYELOPEROXIDASE; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY INDEX; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVITY; EPITHELIUM CELL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; MALE; MOUSE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONHUMAN; PRIORITY JOURNAL; WEIGHT CHANGE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL MARKERS; CELL PROLIFERATION; COLITIS; COLON; DEXTRAN SULFATE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; WEIGHT LOSS;

EID: 84884541899     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.832366     Document Type: Article

References (30)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205
2. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008;14:390-400
3. Chevaux JB, Peyrin-Biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis 2010;17:1428-35
4. Hayashi Y. Metabolic impact of glucagon deficiency. Diabetes Obes Metab 2011;13:151-7
5. Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH, Drucker DJ. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 1997; 138:4837-43
6. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997;272:E1050-8
7. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996;93:7911-16
8. Yazbeck R, Abbott CA, Howarth GS. The use of GLP-2 and related growth factors in intestinal diseases. Curr Opin Investig Drugs 2010;11:440-6
9. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007;21:517-33
10. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-43
11. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-7
12. Yazbeck R, Howarth GS, Geier MS, Demuth HU, Abbott CA. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci 2008;13:6850-8
13. Bank U, Heimburg A, Helmuth M, Stefin S, Lendeckel U, Reinhold D, et al. Triggering endogenous immunosuppressive mechanisms by combined targeting of dipeptidyl peptidase IV (DPIV/CD26) and aminopeptidase N (APN/CD13)- A novel approach for the treatment of inflammatory bowel disease. Int Immunopharmacol 2006;6:1925-34
14. Yazbeck R, Sulda ML, Howarth GS, Bleich A, Raber K, von Horsten S, et al. Dipeptidyl peptidase expression during experimental colitis in mice. Inflamm Bowel Dis 2010;16: 1340-51
15. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49
16. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010;59:1192-9
17. Joly F, Mayeur C, Messing B, Lavergne-Slove A, Cazals-Hatem D, Noordine ML, et al. Morphological adaptation with preserved proliferation/transporter content in the colon of patients with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2009;297:G116-23
18. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K. Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats. Am J Physiol Endocrinol Metab 2010;300:E372-9
19. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94
20. Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, et al. Discovery and pharmacological characterization of N-[2-({2- [(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl} amino)-2-methylpropyl]-2-methyl pyrazolo-[1,5-a] pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 2011;19:7221-7
21. Okawada M, Holst JJ, Teitelbaum DH. Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome. Surgery 2011;150:217-23
22. Ban H, Bamba S, Imaeda H, Inatomi O, Kobori A, Sasaki M, et al. The DPP-IV inhibitor ER-319711 has a proliferative effect on the colonic epithelium and a minimal effect in the amelioration of colitis. Oncol Rep 2011;25: 1699-703
23. Tsai CH, Hill M, Drucker DJ. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol 1997;272:G662-8
24. Dube PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 2006;131:589-605
25. Rowland KJ, Trivedi S, Lee D, Wan K, Kulkarni RN, Holzenberger M, et al. Loss of glucagon-like peptide-2-induced proliferation following intestinal epithelial insulinlike growth factor-1-receptor deletion. Gastroenterology 2011;141:2166-75; e7
26. Howarth GS, Xian CJ, Read LC. Insulin-like growth factor-I partially attenuates colonic damage in rats with experimental colitis induced by oral dextran sulphate sodium. Scand J Gastroenterol 1998;33:180-90
27. Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005;124:105-12
28. Egger B, Procaccino F, Sarosi I, Tolmos J, Buchler MW, Eysselein VE. Keratinocyte growth factor ameliorates dextran sodium sulfate colitis in mice. Dig Dis Sci 1999;44:836-44
29. Miceli R, Hubert M, Santiago G, Yao DL, Coleman TA, Huddleston KA, et al. Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J Pharmacol Exp Ther 1999;290:464-71
30. Ansorge S, Bank U, Heimburg A, Helmuth M, Koch G, Tadje J, et al. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009;47: 253-61